Chemotherapy Induced Peripheral Neuropathy Market

Market Overview

Chemotherapy Induced Peripheral Neuropathy Market is expected to reach US$1,174.26 million by 2030, from US$813.48 million in 2023; it is expected to register a CAGR of 5.4% from 2023 to 2030.

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent side effect that occurs as a result of treatment with antineoplastic agents. It is characterized by sensory neuropathy, primarily affecting sensation, but can also involve motor and autonomic changes to varying degrees. The intensity and duration of these symptoms can vary from patient to patient.

CIPN poses a significant challenge for cancer patients, survivors, and healthcare providers due to its high prevalence and the lack of a universally effective preventive method. Currently, there are limited treatment options available for managing CIPN, further exacerbating the issue.

The impact of CIPN on patients is significant, as it can cause pain, numbness, tingling, and other sensory abnormalities, affecting their quality of life. It may also lead to functional impairment, difficulty with daily activities, and a potential disruption in cancer treatment schedules.

Healthcare providers face the challenge of managing CIPN effectively and addressing patients' symptoms and concerns. Research efforts are focused on understanding the underlying mechanisms of CIPN and identifying potential preventive strategies and treatment options to alleviate its impact on patients.

CIPN is a common and distressing side effect of chemotherapy, characterized by sensory, motor, and autonomic changes. Its high prevalence, lack of a definitive prevention method, and limited treatment options make it a significant problem for cancer patients, survivors, and healthcare providers. Continued research and the development of innovative approaches are essential to mitigate the impact of CIPN and improve the well-being of those affected by it.

Market Dynamics

The dynamics of the Chemotherapy Induced Peripheral Neuropathy (CIPN) market are influenced by various factors. These include the increasing prevalence of cancer, the growing demand for effective management of peripheral neuropathy, advancements in treatment options, and the impact of the COVID-19 pandemic on healthcare systems. Additionally, factors such as the availability of reimbursement policies, regulatory frameworks, and technological advancements play a role in shaping the market dynamics. The market is characterized by ongoing research and development efforts, collaborations between pharmaceutical companies, and the introduction of novel therapies to address the unmet needs of patients suffering from CIPN.


The key drivers of the Chemotherapy Induced Peripheral Neuropathy (CIPN) market include the rising incidence of cancer, the demand for effective management of peripheral neuropathy, and the development of innovative treatment options to alleviate the symptoms associated with CIPN.


The Chemotherapy Induced Peripheral Neuropathy (CIPN) market may face challenges related to the development of drug resistance in patients, which can reduce the effectiveness of treatment options. This resistance can lead to limited response rates and the need for alternative approaches to manage CIPN in affected individuals.

Strategic Insights

The report provides a comprehensive analysis of the Chemotherapy Induced Peripheral Neuropathy (CIPN) market, focusing on industry trends, technological advancements, and market dynamics. It offers valuable insights into the competitive landscape, highlighting key market participants worldwide. Additionally, the report assesses the global impact of the COVID-19 pandemic on the CIPN market.

The COVID-19 pandemic has had a profound effect on public health and the global economy. Prior to the pandemic, the CIPN market was experiencing steady growth due to increased cancer screenings, consultations, and treatment. However, the initial wave of COVID-19 disrupted oncological consultations, follow-ups, and screening procedures, causing a significant impact on the CIPN market.

The pandemic necessitated changes in healthcare delivery, with a shift towards telemedicine and remote consultations. This had both positive and negative implications for the CIPN market. On one hand, telemedicine allowed for continued patient care and monitoring. On the other hand, disruptions in routine screenings and reduced patient visits led to delays in CIPN diagnosis and treatment initiation.

The report provides a detailed analysis of the pandemic's effects on the CIPN market, highlighting the challenges faced by healthcare providers and patients. It also discusses potential strategies and adaptations implemented in response to the pandemic, such as virtual healthcare platforms and innovative approaches to patient management.

Furthermore, delays in clinical trials and patient drug supply during the start of the COVID-19 pandemic impacted the most critical segments of the Chemotherapy Induced Peripheral Neuropathy sector. The focus on the early treatment of COVID-19 has resulted in the ignoring of a number of other medical problems. Furthermore, a decrease in the number of cancer cases diagnosed and chemotherapy sessions administered for treatment has reduced the necessity for chemotherapy-induced peripheral neuropathy diagnoses and therapies.

Market Barriers

The rising prevalence of cancer is a significant driving factor behind the growth of the Chemotherapy Induced Peripheral Neuropathy (CIPN) market. Cancer is a global health concern, and its incidence continues to increase worldwide. According to the World Health Organization (WHO), cancer is a leading cause of death in numerous countries, particularly among individuals under the age of 70.

The data released by WHO in March 2023 highlighted that cancer was responsible for approximately 10 million deaths in 2020. This staggering number emphasizes the urgent need for effective cancer treatments and supportive care measures to improve patient outcomes and quality of life.

Chemotherapy is a commonly used treatment modality for various types of cancer. However, one of the significant side effects associated with chemotherapy is peripheral neuropathy, which can cause pain, numbness, and sensory abnormalities in patients. As the number of cancer cases continues to rise, the incidence of chemotherapy-induced peripheral neuropathy also increases.

The growing recognition of the impact of chemotherapy-induced peripheral neuropathy on cancer patients' quality of life has propelled the demand for effective management and treatment options. Consequently, the CIPN market is experiencing growth to address the unmet needs of patients and provide relief from the debilitating symptoms associated with peripheral neuropathy.

The rising prevalence of cancer, as reported by the WHO, is a key driver of the growth in the Chemotherapy Induced Peripheral Neuropathy market. The increasing number of cancer cases globally underscores the importance of developing and implementing effective strategies to manage and treat chemotherapy-induced peripheral neuropathy, improving the overall care and well-being of cancer patients.

World’s Most Prevalent Forms of Cancer, 2020
The increasing prevalence of cancer has created a burden on healthcare systems across the world, while increasing the demand for chemotherapy. Chemotherapy-induced peripheral neuropathy is a common side effect of neurotoxic anticancer drugs, such as platinum-derived drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concern among cancer patients and survivors, and their healthcare providers, particularly because there is no single effective way to prevent this disease.

In a study conducted by The Journal of the International Association for the Study of Pain, the prevalence of chemotherapy-induced peripheral neuropathy was reported to be 68.1% (57.7 to 78.4 when measured in the first month after chemotherapy, 60.0% (36.4 to 81.6) by month 3, and 30.0% (6.4 to 53.5) by month 6 or later. Rising incidence of Chemotherapy Induced Peripheral Neuropathy along with increasing prevalence of cancer is driving the growth of the Chemotherapy Induced Peripheral Neuropathy market.

Drug Class-Based Insights

The chemotherapy-induced peripheral neuropathy (CIPN) market can be segmented based on drug class, including steroids, antidepressants, anti-epileptics, and narcotics. In 2023, the steroids segment accounted for the largest market share in this segment. Steroids are often used to manage inflammation and reduce pain associated with CIPN. They help alleviate symptoms and improve quality of life for patients undergoing chemotherapy.

Among the different drug classes, the anti-epileptics segment is projected to register the fastest compound annual growth rate (CAGR) of 6.2% during the forecast period. Anti-epileptic medications, such as gabapentin and pregabalin, are commonly prescribed for the treatment of neuropathic pain, including CIPN. These drugs work by modulating the abnormal electrical activity in damaged nerves and providing pain relief.

The growth of the anti-epileptics segment can be attributed to several factors. Firstly, there is an increasing recognition of their effectiveness in managing neuropathic pain, including CIPN, leading to their widespread use. Additionally, the development of new and improved formulations of anti-epileptic drugs with enhanced efficacy and tolerability contributes to their market growth. Moreover, the rising incidence of chemotherapy-induced peripheral neuropathy and the growing focus on improving patient outcomes are driving the demand for effective treatment options, including anti-epileptics.

In conclusion, the CIPN market is segmented based on drug class, with steroids currently holding the largest market share. However, the anti-epileptics segment is expected to exhibit the fastest growth rate during the forecast period. This is attributed to the effectiveness of anti-epileptic medications in managing neuropathic pain and the increasing demand for improved treatment options for chemotherapy-induced peripheral neuropathy.

Distribution Channel-Based Insights

The Chemotherapy Induced Peripheral Neuropathy market is divided into three segments based on distribution channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The hospital pharmacy category maintained the greatest market share in 2023. Furthermore, the retail pharmacy category is predicted to grow at the fastest rate of 5.9% between 2023 and 2030.

To increase their footprint and product portfolio internationally, as well as to satisfy rising demand, Chemotherapy Induced Peripheral Neuropathy (CIPN) market participants are focusing on organic tactics such as product introduction and expansion.


The Chemotherapy Induced Peripheral Neuropathy (CIPN) market has witnessed significant developments in recent years. Here are some key developments in this field:

Development of Novel Therapies: Researchers and pharmaceutical companies are actively exploring new treatment options for CIPN. Various clinical trials are underway to evaluate the efficacy and safety of novel drugs specifically targeting peripheral neuropathy induced by chemotherapy. These developments aim to provide better symptom management and improve the quality of life for patients.

Focus on Neuroprotective Agents: Neuroprotective agents have gained attention in the management of CIPN. These agents aim to protect the nerves from damage caused by chemotherapy drugs. Some promising neuroprotective agents being investigated include antioxidants, growth factors, and certain medications that can potentially prevent or reduce the severity of CIPN.

Advances in Non-Pharmacological Interventions: Non-pharmacological interventions, such as physical therapy, exercise, acupuncture, and complementary therapies, are being explored as adjunctive treatments for CIPN. These interventions focus on improving nerve function, reducing pain, and enhancing overall well-being in patients.

Personalized Medicine Approaches: With advancements in genetic profiling and molecular testing, there is a growing interest in personalized medicine approaches for CIPN. Identifying genetic variations or biomarkers associated with increased susceptibility or severity of CIPN can help tailor treatment strategies for individual patients, leading to better outcomes.

Supportive Care Strategies: Healthcare providers are placing greater emphasis on supportive care strategies for CIPN management. These strategies involve a multidisciplinary approach, including pain management, patient education, and psychosocial support. Supportive care aims to address the physical, emotional, and social aspects of CIPN, improving patients' overall well-being.

By Geography

The market for Chemotherapy Induced Peripheral Neuropathy (CIPN) can be analyzed geographically, taking into account different regions such as North America, Latin America, Asia Pacific, and the Middle East and Africa. Each region presents unique characteristics and factors that influence the CIPN market.

North America is a prominent market for CIPN due to its advanced healthcare infrastructure, significant investment in research and development, and high prevalence of cancer cases. The region has a well-established pharmaceutical industry, which drives the development and availability of various treatment options for CIPN. Additionally, supportive reimbursement policies and a high awareness level among healthcare professionals contribute to the growth of the CIPN market in North America.

In Latin America, the CIPN market is experiencing gradual growth. The region has an increasing burden of cancer cases and a growing emphasis on improving cancer care. However, limited access to advanced healthcare facilities, affordability issues, and inadequate awareness about CIPN among healthcare providers and patients pose challenges to market growth in this region.

Asia Pacific is witnessing significant growth in the CIPN market. The region has a large patient population, increasing incidence of cancer, and improving healthcare infrastructure. Countries like China, India, and Japan have shown substantial investments in cancer research and treatment, leading to the development of new therapies for CIPN. Moreover, the presence of a large pharmaceutical manufacturing base in the region enhances the availability and accessibility of CIPN treatments.

The Middle East and Africa region exhibit a relatively smaller market for CIPN due to limited healthcare resources and challenges in accessing advanced cancer care. However, the region is witnessing improvements in healthcare infrastructure, rising awareness about cancer, and increasing efforts to enhance cancer treatment facilities. As a result, the CIPN market in this region is gradually expanding.

The geographical analysis of the CIPN market across North America, Latin America, Asia Pacific, and the Middle East and Africa highlights the varying market dynamics and factors influencing market growth in each region. Factors such as healthcare infrastructure, reimbursement policies, cancer prevalence, and awareness levels play a crucial role in shaping the CIPN market landscape in these regions.

Company Profiles

  • Regenacy Pharmaceuticals, Inc.
  • Asahi Kasei Pharma Corporation
  • Novaremed
  • Makscientific, Llc
  • Wex Pharmaceuticals Inc.
  • Sova Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Aptinyx Inc.
  • Apexian Pharmaceuticals, Inc.
  • Winsantor, Inc.    

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!


One of our marquee services We profile relevant start-up companies in the market.


Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.